Portfolio

Immitra Bio is a spin-off from ETH Zurich developing a next-generation platform for in vivo gene editing targeting rare genetic disorders. While current gene therapies require chemotherapy and highly personalized processes that are costly, cause serious side effects and are inaccessible to most patients, Immitra Bio's approach enables a single, off-the-shelf injection that corrects genetic defects directly in the body – without side effects.

Lymphatica Medtech is a medical device com­pa­ny from Lausanne com­mit­ted to sig­nif­icant­ly improving the well-being of patients suf­fer­ing from lym­phat­ic diseases. The com­pa­ny has in­te­grat­ed an in­no­va­tive pumping tech­nol­ogy into a sub­cutaneous implant activated by a wear­able device, with the aim to effectively replace the lym­phat­ic drainage function without impact­ing the patient’s life­style.

Altavo is a Dresden-based Med­tech start-up with the vision of improving the reha­­­­bili­tation and quality of life of people without a voice. Based on a combi­­nation of AI algo­rithms and non-invasive radar sensor techno­logy, the company is deve­loping an arti­ficial voice that sets new standards in terms of voice quality and user-friendli­ness. The first field of appli­cation is cancer patients who have lost their voice after laryn­­gectomy.

Chipmetrics sets a new standard by develo­ping and manu­­facturing inno­vative metrology chips and wafers for the semi­con­ductor industry. The Finnish company is the leading expert in con­formality measure­­ments of thin films using 3D high aspect ratio test elements. Appli­­cations are in thin film process develop­­ment, tool quali­­fication and quality assurance in semi­­conductor and advanced materials manu­­facturing – a rapidly growing and evolving industry.

ReCatalyst is a Slovenian spin-off company of the National Institute of Chemistry in Ljubljana, developing inno­vative catalysts for fuel cells. The company is building a ground­breaking nano­­technology plat­form for the pro­duction of cutting-edge (electro)catalysts for fuel cells and water electro­lyzers with the mission to opti­mize the use of plati­num group metals. The company is dedi­cated to accelerating the decarbo­ni­zation of the energy and trans­port sectors.

EBAMed is a Geneva-based medical device company active in the ambitious field of proton therapy. The company is developing a novel treat­­ment system to monitor and react to heart move­ment during cardiac radio­ablation proce­­dures. The aim is to reduce the volume of healthy heart exposed to more than 20 gray of protons/photons during cardiac radio ablation, thereby maxi­­mizing long-term safety for patients.

core sensing from Darm­stadt develops an inno­vative sensor techno­logy that uses smart sensors inside mechanical compo­nents in combi­nation with intelli­gent algorithms to provide valuable insights into machines, plants and commercial vehicles. This allows them to be digitized and thus operated more efficiently, potential problems to be detected at an early stage, expensive scrap and down­time costs to be avoided, and new digital business models to be imple­mented.

Avelo is a Zurich-based diagnostics startup developing a simple breath collector to improve the diagnosis of tuber­culosis and other respiratory infections that cause pneumonia – the fourth leading cause of death worldwide. The breath collector will enable non-invasive and painless samples, particularly from the lower respiratory tract, which can be analyzed with existing PCR testing infra­structure.

hemotune is developing a unique approach to extra­corporeal blood purification. The HemoSystem platform techno­logy uses magnetic nano­particles to selectively remove previously inaccessible bio­molecules from the blood. Initially, the method is to be used primarily in cases of an uncontrolled immune reaction (septic shock). In addition, the plat­form can also be used for a variety of other indi­cations.

Algiax Pharmaceuticals researches and develops inno­vative pro­ducts for the treat­ment of diseases with high unmet medical demand. The core of the develop­ment is AP-325, a low-molecular GABA_A receptor modulator, which is currently in clinical develop­ment as a therapy for neuro­pathic pain.

Thermosome is a clinical-stage drug develop­ment company focused on targeted tumor therapy with immune stimu­lation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for increased local drug concen­trations and improved tumor pene­tration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermo­sensitive formu­lation of doxorubicin being developed in soft tissue sarcoma.

Resistell is developing a technology for quicker, more precise antibiotic susceptibility testing. After bacteria have been exposed to antibiotics, their effect can be demons­trated by the changing move­ment of bacterial cells. In comparison to a culture-based anti­biogram, this method provides results within a few hours. This allows patients to receive the right medi­cation in the right concen­tration, from day one.

G-Metrics designs, produces and distributes disruptive solutions for ophthal­mology, particularly for glaucoma patients. The CE-approved eyemate® system combines state-of-the-art medical techno­logy with digital health solutions and therefore enables more efficient therapy and disease manage­ment.

InSphero offers advanced yet easy-to-use tissue-based 3D assay solutions for predictive drug classi­fication to bring more reliable, effective drugs to the market faster. The core of the solution are the physio­logically relevant 3D InSight™ platforms and associated microchip technologies.

iMusician provides copyright services to musicians around the world. The company monetizes copyrights, organizes digital distri­bution, handles license fees and also offers mastering of tracks for tens of thousands of musicians.

Tubulis used proprietary techno­logies to develop novel drugs whose mecha­nisms of operation address the deep-seated causes of the respective disease. The goal was to expand the thera­peutic potential of Antibody Drug Conjugates (ADCs) to enable more targeted and effective treat­ment of cancer and other diseases. Tubulis was sold to Gilead Sciences (NASDAQ:GILD) in 2026 for $3.15 billion, plus contingent milestone payments of up to $1.85 billion.

adivo developed a technology platform for the selection of species-specific thera­peutic anti­bodies for veterinary medicine. These anti­bodies had predefined characte­ristics that enabled the generation of lead candidates with optimal functio­nality for dogs and other animals. After the ongoing colla­boration in canine antibody drug discovery since 2021, which was expanded to include adivo’s novel feline antibody library in 2022, the exit to Zoetis Inc. (NYSE:ZTS), the global leader in animal health, took place in 2023.

Lunaphore was developing an immuno­histo­chemical testing procedure that uses micro­fluidic systems to achieve faster, more precise analysis of tumor tissue. In addition, Lunaphore enabled digital pathology by inte­grating imaging systems such as a micro­scope with sequential data extraction. Lunaphore was acquired by the global life sciences company Bio-Techne Corporation (NASDAQ:TECH) in 2023.

Versantis developed drugs and diagnostics for the treatment of acute and chronic liver failure with the aim of revolutionizing previous standards of care. The lead project VS-01 was in pre-clinical phase 2 at exit with the potential to become a first-line therapy for chronic liver failure. Versantis was acquired by GENFIT in September 2022 to jointly continue the develop­ment of its revolutionary therapeutics.

GNA Biosolutions developed a disruptive PCA (Pulse Controlled Amplification) technology for DNA analysis from complex clinical samples. GNA’s technology delivers results within a few minutes and is therefore significantly faster and cheaper than other solutions in the field of mole­cular diagnostics. GNA’s rapid tests were also used for the diagnosis of COVID-19.

cunesoft developed an innovative software platform for the pharma­ceutical industry’s regulatory processes, which leads to more efficient processes and thus to easier and faster drug approval. In early 2020, the company exited to Phlexglobal, a leading provider of technologies and services in the clinical and regulatory area.

kooaba developed an augmented reality technology platform for image recognition on mobile devices. By enriching it with additional information about the identified object, an exciting combination of the physical world with digital content is created. In 2014, kooaba was acquired by Qualcomm, one of the world’s largest semiconductor manufacturers and suppliers of products for mobile communications.